Nasdaq Chrs News Today

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...

Peregrine Capital Management LLC lowered its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 20.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,089,961 shares of the biotechnology company’s stock after selling 288,606 shares during the quarter. Peregrine Capital Management […]

Peregrine Capital Management LLC trimmed its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 20.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,089,961 shares of the biotechnology company’s stock after selling 288,606 shares […]

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety...

E Fund Management Co. Ltd. purchased a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 45,010 shares of the biotechnology company’s stock, valued at approximately $168,000. Several other institutional investors also recently bought and sold shares of […]

Coherus BioSciences (NASDAQ:CHRS – Get Free Report) and Novavax (NASDAQ:NVAX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends. Profitability This table compares Coherus BioSciences and Novavax’s […]

Dorsey & Whitney Trust CO LLC bought a new stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,410 shares of the biotechnology company’s stock, valued at approximately $39,000. A number of other large investors […]

Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,410 shares of the biotechnology company’s stock, valued at approximately $39,000. Several […]

Coherus BioSciences (NASDAQ:CHRS – Free Report) had its target price reduced by Robert W. Baird from $11.00 to $9.00 in a report published on Tuesday, Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the company. Truist Financial cut their […]